Brokerages predict that Achaogen, Inc. (NASDAQ:AKAO) will announce earnings of ($0.72) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Achaogen’s earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.81). Achaogen posted earnings per share of ($0.41) in the same quarter last year, which suggests a negative year over year growth rate of 75.6%. The business is expected to announce its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Achaogen will report full-year earnings of ($2.99) per share for the current financial year, with EPS estimates ranging from ($3.50) to ($2.70). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.73) per share, with EPS estimates ranging from ($3.32) to ($2.00). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Achaogen.

Achaogen (NASDAQ:AKAO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.18). The business had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $2.69 million. Achaogen had a negative return on equity of 86.24% and a negative net margin of 281.88%. Achaogen’s revenue for the quarter was down 85.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.87) EPS.

Several research firms have recently commented on AKAO. Zacks Investment Research raised shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price target for the company in a research report on Monday, July 17th. BidaskClub raised shares of Achaogen from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. HC Wainwright began coverage on shares of Achaogen in a research report on Thursday, June 15th. They set a “buy” rating and a $29.00 price target for the company. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Mizuho began coverage on shares of Achaogen in a research report on Wednesday, September 6th. They set a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $26.07.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/0-72-earnings-per-share-expected-for-achaogen-inc-akao-this-quarter.html.

Achaogen (AKAO) traded up 0.79% during trading on Friday, hitting $16.49. 1,400,449 shares of the stock traded hands. Achaogen has a 52-week low of $3.68 and a 52-week high of $27.79. The company’s market cap is $696.42 million. The firm has a 50-day moving average price of $18.09 and a 200 day moving average price of $21.84.

Institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can increased its holdings in Achaogen by 25.0% in the 1st quarter. Bank of Montreal Can now owns 7,500 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 1,500 shares in the last quarter. Legal & General Group Plc purchased a new stake in Achaogen in the 2nd quarter worth approximately $168,000. Oppenheimer Asset Management Inc. purchased a new stake in Achaogen in the 1st quarter worth approximately $199,000. Sigma Planning Corp increased its holdings in Achaogen by 9.6% in the 2nd quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 825 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Achaogen by 691.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 9,677 shares in the last quarter. 84.12% of the stock is owned by institutional investors.

About Achaogen

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).